# Changes in Insulin Resistance with Different Weight Loss Methods in Patients with Type Two Diabetes Mellitus and Hypertension: A Comparative Clinical Trial

**Authors:** Kuat Oshakbayev, Aigul Durmanova, Gani Kuttymuratov, Nurzhan Bikhanov, Altay Nabiyev, Timur Suleimenov, Alisher Idrissov, Tomiris Shakhmarova, Zhanel Mirmanova, Saule Rakhimova, Ulan Kozhamkulov, Ainur Akilzhanova

PMC · DOI: 10.3390/jcm15020546 · 2026-01-09

## TL;DR

This study compares how different weight loss methods affect insulin resistance in patients with type 2 diabetes and hypertension.

## Contribution

The study provides a direct comparison of pharmacological treatment, bariatric surgery, and a very-low-calorie diet on insulin resistance and blood pressure.

## Key findings

- Bariatric surgery and very-low-calorie diet significantly reduced weight and insulin resistance more than pharmacological treatment.
- Greater weight loss correlated with a larger decrease in insulin resistance, with a 10% weight loss reducing HOMA-IR by 65%.
- Weight loss reduced the need for antidiabetic and antihypertensive medications in patients with T2DM and hypertension.

## Abstract

Background: The comparative effects of pharmacological treatment, bariatric surgery, and diet on insulin resistance (IR) remain unclear. Aim: To study the comparative effects of the methods on IR: pharmacologic, bariatric surgery, and very-low-calorie diet (VLCD) in patients with type 2 diabetes mellitus (T2DM) and hypertension. Methods: Design: a 90-day prospective, multicenter, comparative clinical trial including 130 adult patients divided into three groups: Drug, Surgery, and VLCD. Endpoints: HOMA-IR; weight loss; and HbA1c, systolic/diastolic blood pressure (SBP/DBP). Results: At 90 days, weight loss in the Surgery (−19.8%) and VLCD groups (−17.4%) was significant (p < 0.0001), while in the Drug group, the loss was insignificant (−6.5%; p = 0.06). SBP/DBP in the Drug group decreased by −9.5% (p = 0.0002) and −4.1% (p = 0.09), respectively. SBP/DBP in the Surgery group decreased by −13.6% and −10.6%, respectively (p < 0.001), and in the VLCD group, by −23.3% and 21.3%, respectively (p < 0.0001). HOMA-IR in Drug, Surgery, and VLCD groups decreased by −42.2% (p = 0.004), −87.6% (p < 0.0001), and −88.7% (p < 0.0001), respectively. In the Drug group, HOMA-IR did not reach the normal level. Correlation-regression analysis revealed a direct correlation between weight loss and a decrease in HOMA-IR (r = 0.526; F = 33.2, p < 0.0001). HOMA-IR decreases by 65% if weight decreases by 10%; if weight decreases by 25%, then HOMA-IR decreases by 83%. Conclusions: HOMA-IR was associated with weight loss: the greater the weight loss, the lower the HOMA-IR. Weight loss leads to a reduction in the need for antidiabetic/antihypertensive drugs in patients with T2DM and hypertension.

## Linked entities

- **Diseases:** type 2 diabetes mellitus (MONDO:0005148)

## Full-text entities

- **Diseases:** IR (MESH:D007333), Type Two Diabetes Mellitus (MESH:D003920), Weight Loss (MESH:D015431), T2DM (MESH:D003924), Hypertension (MESH:D006973)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12842082/full.md

---
Source: https://tomesphere.com/paper/PMC12842082